T‐DM1 extravasation: first description
- 16 April 2015
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (7), 1235-1236
- https://doi.org/10.1111/jdv.13164
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- T-DM1-related telangiectasias: a potential role in secondary bleeding eventsAnnals of Oncology, 2015
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety AnalysisJournal of Clinical Oncology, 2014
- Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case seriesBreast Cancer Research and Treatment, 2014
- Taxanes: vesicants, irritants, or just irritating?Therapeutic Advances in Medical Oncology, 2013
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancerCurrent Medical Research and Opinion, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Management of chemotherapy extravasation: ESMO–EONS Clinical Practice GuidelinesAnnals of Oncology, 2012
- Extravasation Management: Clinical UpdateSeminars in Oncology Nursing, 2011
- Extravasation of ChemotherapyCurrent Oncology Reports, 2010
- Extravasation of systemic hemato-oncological therapiesAnnals of Oncology, 2004